Andy has over 25 years’ experience of driving performance improvements in multi-brand international business in a diverse range of sectors, and Dr Burton brings a wealth of pharmaceutical industry experience to Immodulon.
The appointments come at a time that marks a new phase in Immodulon’s development as an immuno-oncology company, with ambition to establish itself as a leading independent player in the global market for immunotherapy, an exciting and clinically vital therapeutic class that has the potential to revolutionise the treatment of cancer.
Board Director Hugo Mackenzie Smith commented: “Andy Clarke is a highly capable and respected leader, and we are confident that his business acumen and retail sector experience will afford Immodulon with invaluable insight and a fresh perspective as it accelerates on its journey to market. “
Andy Clarke commented: “Joining Immodulon represents an exciting shift in focus for me. I am looking forward to spearheading the development of a growing company looking to commercialise truly innovative products in the field of immunotherapy, and tackle some of the world’s deadliest illnesses. I am delighted to be supported in this endeavour by a highly experienced and well-established Board and management team, formed of leaders in their respective fields.”